EGFR and non-small cell lung carcinoma: These results suggest that the addition of ginsenoside Rg3 to EGFR-TKI reduces drug resistance in the treatment of NSCLC patients with EGFR-active mutations, and that ginsenoside Rg3 could be an important agent for improving median PFS and delaying the acquisition of resistance to EGFR-TKI in patients.